STML - Stemline Therapeutics, Inc.
| Previous Close | 17.20 |
| Open | 17.10 |
| Bid | 15.80 x 200 |
| Ask | 19.85 x 700 |
| Day's Range | 17.00 - 17.60 |
| 52 Week Range | 7.30 - 18.75 |
| Volume | 171,506 |
| Avg. Volume | 358,942 |
| Market Cap | 481.698M |
| Beta | 1.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.94 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.67 |
- GlobeNewswire•5 days ago
Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline
NEW YORK, April 16, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced expansion of its Board of Directors to include ...
- ACCESSWIRE•12 days ago
Wired News – Stemline Therapeutics Initiates Rolling BLA Submission for SL-401
Stock Monitor: Cyclacel Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Stemline Therapeutics, Inc. (NASDAQ: STML ...
- GlobeNewswire•16 days ago
Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401
NEW YORK, April 05, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has initiated its rolling submission of ...
- GlobeNewswire•last month
Report: Exploring Fundamental Drivers Behind Fluidigm, Acuity Brands, TTEC, Actuant, Equity Lifestyle Properties, and Stemline Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•last month
Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference
NEW YORK, March 19, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’ s CEO, will ...
- Associated Press•last month
Stemline Therapeutics reports 4Q loss
On a per-share basis, the New York-based company said it had a loss of 93 cents. For the year, the company reported that its loss widened to $67.8 million, or $2.94 per share. Revenue was reported as $898,000. ...
- GlobeNewswire•last month
Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results
NEW YORK, March 16, 2018--. Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial results for the quarter ended December ...
- Simply Wall St.•last month
Breakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)
Stemline Therapeutics Inc’s (NASDAQ:STML): Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The US$504.11M market-capRead More...
- GlobeNewswire•last month
Stemline Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, March 08, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that Ivan Bergstein, M.D., ...
- Simply Wall St.•3 months ago
Top 3 Growth Stocks For The Month
High-growth stocks that are financially stable are attractive for many reasons. They provide a strong upside to your portfolio, with less likelihood of downside risks compared to less financially robustRead More...
- GlobeNewswire•3 months ago
Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock
NEW YORK, Jan. 26, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing of a previously announced underwritten ...
- GlobeNewswire•3 months ago
Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock
NEW YORK, Jan. 24, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing of an underwritten public offering ...
- GlobeNewswire•3 months ago
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
NEW YORK, Jan. 22, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it intends to offer and sell, subject to market ...
- Business Wire•3 months ago
Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
- Capital Cube•4 months ago
ETFs with exposure to Stemline Therapeutics, Inc. : December 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Stemline Therapeutics, Inc. Here are 5 ETFs with the largest exposure to STML-US. Comparing the performance and risk of Stemline Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Simply Wall St.•4 months ago
Best-In-Class Growth Stocks
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...
Capital Cube•4 months agoStemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
Categories: Yahoo FinanceGet free summary analysis Stemline Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Stemline Therapeutics, Inc. – Cyclacel Pharmaceuticals, Inc., Verastem, Inc., Agenus Inc., Celgene Corporation, Sunesis Pharmaceuticals, Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc. and ImmunoCellular Therapeutics, Ltd. (CYCC-US, VSTM-US, AGEN-US, ... Read more (Read more...)
- Associated Press•5 months ago
Stemline Therapeutics reports 3Q loss
The New York-based company said it had a loss of 68 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
